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Abstract: Biomolecular recognition using a multivalent strategy has been successfully applied,
this last decade on several biological targets, especially carbohydrate-processing enzymes, proteases,
and phosphorylases. This strategy is based on the fact that multivalent interactions of several
inhibitory binding units grafted on a presentation platform may enhance the binding affinity and
selectivity. The zinc metalloenzymes carbonic anhydrases (CAs, EC 4.2.1.1) are considered as drug
targets for several pathologies, and different inhibitors found clinical applications as diuretics,
antiglaucoma agents, anticonvulsants, and anticancer agents/diagnostic tools. Their main drawback
is related to the lack of isoform selectivity leading to serious side effects for all pathologies in which
they are employed. Thus, the multivalent approach may open new opportunities in the drug design
of innovative isoform-selective carbonic anhydrase inhibitors with biomedical applications.
Keywords: carbonic anhydrases; inhibitors; multivalency; multivalent; CA isoforms; multifunctionnal
scaffold
1. Introduction
Human carbonic anhydrases (hCA, EC 4.2.1.1) are ubiquitous zinc enzymes of medical relevance
that belong to the lyase family. These metalloproteins are efficient catalysts for the hydration of
carbon dioxide to bicarbonate and protons playing crucial physiological/pathological roles in acid-base
homeostasis, secretion of electrolytes, transport of ions, biosynthetic reactions, and tumorigenesis.
X-ray crystallography data showed that zinc ion is situated at the bottom of a 15 Å deep active site cleft
being coordinated by three histidine residues and a hydroxide ion. The catalytic mechanism takes
place by the attack of HO− on the CO2 molecule located in a neighboring hydrophobic pocket leading
to the formation of bicarbonate coordinated to Zn ion. The bicarbonate is then displaced by a water
molecule and released into the solution leading to the catalytically inactive acid form of the enzyme.
The regeneration of the basic form is carried out by a proton transfer reaction from the active site to
the environment with the assistance of histidine residues. There are 15 known isoforms in humans,
and 12 of them are enzymatically active, and thus considered targets of carbonic anhydrase inhibitors
(CAIs). By taking advantage of 40 years of research and with the help of structural studies, different
drug design campaigns inspired new ideas and contributed significantly to the discovery of effective
inhibitors with diuretics, antiglaucoma, anticancer, or antiobesity properties, or for the management of
a variety of neurological disorders, including epilepsy and altitude disease [1].
Nevertheless, even if the potency of carbonic anhydrase inhibitors has been greatly improved
in the last years, with inhibitors reaching inhibition constant in the femtomolar range, the selectivity
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issue remains important. Small molecules approach, featuring classic medicinal chemistry and rational
drug design, is still relevant and, therefore, always the subject of intense research efforts [2].
Another interesting strategy that appeared recently to address the selectivity of CAIs against
specific isoforms is the use of multivalent CA-directed pharmacologic agents. The idea behind this
approach is that considering the thermodynamic modifications in binding upon going from the
monovalent to the multivalent systems can be exploited to improve affinity but above all the selectivity,
meaning that an inhibitor may become more effective and more selective in a cluster than alone.
Moreover, the multivalency approach could be leveraged for changing low-affinity and weakly selective
inhibitors into potent and selective inhibitors [3].
Multivalent nanoconstructs are generally prepared by the conjugation of inhibitors onto high
or low valency preorganized (such as for example cyclopeptide) or disordered (such as dendrimers)
multifunctional (bio)molecular chemical framework using different conjugation methodologies,
especially click reactions [3].
Multimeric enzyme inhibition is not something particularly easy to implement. Attaching multiple
inhibitors to a molecular platform does not necessarily lead to an effective multivalent system knowing
that structural parameters such as topology, structure, and valency of the platform, length and rigidity
of the ligation system, are among the many parameters to be refined in order to observe and improve
multivalent effects.
This approach is thus of great interest for the medicinal chemist, in particular, for the design of
enzyme inhibitors. It has been successfully used in glycosidase and glycosyltransferase inhibition [3–6].
Almost restricted to these family of carbohydrate-processing enzymes, few research works were
reported on other enzyme families such as metalloproteases [7].
In the field of zinc metalloenzymes, pioneering work had been initiated in 2003 in the context of
divalent CAIs exploiting the hydrophobic and the hydrophilic binding sites of hCA isoforms [8–10].
The interesting results obtained from these studies have contributed to the development of multimeric
CAIs and our research groups were the first to report the application of this strategy on carbonic
anhydrases using gold nanoparticles [11].
In this paper, we shall review the state of the art of the multivalent inhibition approach applied to
carbonic anhydrases and its potential in both diagnostic and therapy.
2. Nanoparticles
Nanoparticles coated with CAIs revealed to be particularly effective in targeting selectively the
hCA isoforms expressed extracellularly, such as the tumor-associated IX [11–14]. Since nanomaterial
usually possesses the size and physicochemical features which do not allow them to bypass the
cellular membranes, and thus to access into the intracellular lumen, they represent ideal platforms to
address target selectivity and multivalent effect. Usually, the contact of nano-objects with the cellular
membranes activates internalization processes by endocytosis, which still prevents xenobiotics from
getting in contact with the cell machinery located within the cytosol.
2.1. Gold Nanoparticles and Nanorods
Some of us firstly proved the use of gold nanoparticles fully coated with CAIs of the sulfonamide
type, which was synthesized according to Scheme 1 reported below [11].
The synthetic procedure to obtain the desired organic intermediates consisted of ordinary amide
reaction couplings of an appropriate amine on the (±) lipoic acid 1 moiety. The latter was chosen as for
its 1,2-dithiolanic moiety, which ensures a tight binding to gold shells as well as acts as an optimal spacer,
and thus, it prevents the sulfonamide moieties the be too close to each other once the nanoparticle
surface is functionalized. The full coated shell was synthesized in one-pot reaction by reduction of
acid chloroaurate with NaBH4 in the presence of the lipoic amides 3a and 3b previously reported.
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Scheme 1. Synthesis of CAI coated gold nanoparticles [11].
The same strategy was successfully used to prepare both the CAI and the thiazolyl coated gold
nanoparticles 4a and 4b, which were fully characterized by means of Transmission Electron Microscopy
(TEM), Energy Dispersive X-ray analysis (EDX), and elemental analyses. All the data retrieved showed
the nan particles being monodispersed, roughly spheric l n shape and with an average size of 3.3 nm,
which corresponds to 720–724 Au a oms. A calculate estima on indicated the numb r of ligand
molecules per particle being of 144 and 135 for 4a and 4b, respectively. The synthetic procedures were
reproducible as multiple batch preparations afforded coated nanoparticles with almost superimposed
features [11].
4a and 4b were tested in vitro for their ability in inhibiting the CA catalyzed CO2 hydration
reaction by means of the stopped-flow technique and compared to the standard CAI acetazolamide
(AAZ) (Table 1). The study focused on the physiologically relevant hCAs I, II, and IX isoforms.
Table 1. CA inhibition d ta against intermediates 3a and 3b coated nanoparticles 4a and 4b and Au
shell against the hCAs I, II, and IX in comparison with the st ndard CAI AAZ. Data in parentheses
refer to the KI values after 2 h of incubation [11].
Compound
KI (nM) *
hCA I hCA II hCA IX
3a 214 ± 9 230 ± 10 41 ± 2
3b >50000 50000 >50000
4a 581 ± 18 (128) 451 ± 21 (116) 32 ± 2 (34)
4b 28550 30400 31050
Au 32000 31600 29560
AAZ 250 (± 2) 12 (± 1) 25 (± 1)
* Mean from three different assays, by a stopped-flow technique (errors were in the range of ± 5–10 % of the
reported values).
The kinetic assay performed at 15 min incubation showed 3a and 4a being modest hCA I inhibitors
(KIs of 214–581 nM), comparable to the reference AAZ (KI 250 nM). In analogy, 3a and 4a showed high
nanomolar KI values against the hCA II (KIs of 230–451 nM). Predictably 3b and 4b, which are devoid
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of any CAI functionality, resulted ineffectively. Quite interestingly, 3a and its corresponding coated
nanoparticle 4a were quite potent inhibitors of the tumor-associated hCA IX with KI value of 41 and
32 nM, respectively, and thus comparable to the reference AAZ (KI of 25 nM), whereas the remaining
compounds were ineffective. The same experiments were also repeated after 2 h incubation (Table 1
numbers in brackets) and interestingly 4a (but not its free ligand) showed enhanced inhibitory activity
against all three isozymes (KIs of 128, 116 and 34 nM against hCA I, II, and IX, respectively). Overall,
4a showed good selectivity in inhibiting the tumor-associated isoform in vitro. Since the kinetic assays
were performed in solution on the hCA IX catalytic domain, such results may be rationalized only with
the preferential binding of the CAI coated nanoparticle with specific amino acidic residues exposed
within the enzymatic cleft. The penetrability of CAIs 3a, 4a, and AAZ through membranes was
investigated by determining the erythrocyte expressed hCAs I and II inhibition. The measurements
were performed up to 24 h time using millimolar concentrations of the CAIs. The results clearly
showed AAZ and sulfonamide 3a led to saturation of the two isozymes after 30–60 min, whereas 4a
was not able to determine any response, thus proving that the CAI coated nanoparticles were unable
to penetrate through biological membranes.
As an extension of such an investigation, we set up a one-pot preparation method of aqueous
dispersions of CAI-coated gold nanoparticles on the 4a type, based on a modified citrate synthesis
procedure, with the final intent to obtain highly dispersible and stable formulations [10]. All the
obtained compounds were properly characterized for their physical-chemical features by means
of Dynamic Light Scattering (DLS), Small Angle X-ray Scattering (SAXS), electrophoretic mobility,
UV-visible spectroscopy, Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES),
and Thermogravimetric Analysis (TGA) experiments. The optimized procedure allowed to obtain
high reproducibility CAI coated nanoparticles dispersed in an aqueous medium, which proved to be
stable for months at room temperature (r.t.). The kinetic assay of such samples on the hCAs I, II, IX,
and XII matched the results previously reported [11], and thus, giving further sustainment to the proof
on the use of CAI coated gold nanoparticles as efficient and reliable systems to properly target hCAs
for biomedical purposes [11,12].
A quite advanced application on CAI-functionalized gold nanoparticles for the management of
hypoxic tumors was recently reported by the Ilies group in 2018 [13]. On the basis of the author’s
previous contributions [13], this work considered the use of the acetazolamide (AAZ) CAI intermediates
5 and 6 as coatings, and their synthesis was performed according to Scheme 2.
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As previously discussed, also in this case, the authors did use the 1,2-dithiolane moiety of the
(±)-lipoic acid as an anchoring group to the gold nanoparticles surface which was produced by the
classical citrate method [13]. The materials obtained were thus characterized and properly assessed for
their ability to interact with tumor cells. In particular, the in vitro tests carried out on colorectal HT-29
cell lines showed the nanoparticles bearing the CAI coating of type 6 were significantly internalized
when hypoxic conditions were established. Such a result was rationalized as mediated by endocytosis
uptake processes, which were triggered after binding of the CAI functionalized nanoparticles with the
hypoxic expressed hCA IX. Different strategies to maximize the loading of doxorubicin (Dox) on the
CAI functionalized nanoparticles were explored by using the precursors reported in Figure 1.
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Figure 1. Structure of Doxorubicin conjugates 7–10 used for loading onto the CAI gold nanoparticles [13].
Among the various structures reported above, the conjugate 10 best maintained the appropriate
physical-chemical features of the entire system. The in vitro tests on HT-29 cell lines clearly showed
the high ability of such functionalized nanoparticles in killing them quite efficiently under hypoxia
and thus when the hCA IX is overexpressed. Analogous results were obtained when HT-29 spheroids
were used. Fluores ence spectroscopy pr ved that doxorubicin delivery by using the CAI coated
nanoparticles resulted enhanced wh n compare to the standard administration in solution. Overall,
such a work proofed the u e of CAI coated nanoparticles s highly efficient and selective delivery
systems f considerable cytotoxic payloads, and thus paving the way to introduce m re effective
ph rmacological t eatments of ypoxic tumors verexpressing the hCA IX.
2.2. Silica Nanoparticles
In the continuity of our work on nanoparticle-type platforms, we reported in 2015, the design
and the sy thesis of multivalent nanometer-sized fluorescent hybrid silica (NFHS) decorated with
sulfonamide carbonic anhydrase inhibitors. [14] They were prepared by grafting silylated inhibitor
ligand 11, on the fluorescent silica nanoparticle 13 previously obtained by co-hydrolysis and
polycondensation of the fluorescent silylated precursor 12 and tetramethoxysilane under basic catalysis
(Scheme 3) [14]. NFHS 14 with a diameter of about (3.5 ± 0.8) nm were characterized as non-porous,
and the evaluation of the number of sulfonamide ligands was estimated between 12 and 14.
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Inhibition study realized with a stopped-flow CO2 hydration assay method against cytosolic
isoforms hCA I, hCA II as well as the two tumor-associated isoforms hCA IX and hCA XII showed a
low nanomolar activity of NHFS 14 with inhibitory activity ranging from 0.67 to 6.2 nM against all
tested isozymes. Comparison of the inhibitory activity of the multivalent NHFS 14 vs. the monovalent
inhibitor, revealed an increased inhibitory potency for the multivalent system respectively of 32 times
for hCA I, 72 times for hCA II, 14 times for hCA IX and 5 times for hCA XII. Multivalent effects were
detected only with hCA I and hCA II with a relative potency normalized to the sulfonamide units
(rp/n) being equal respectively to 2.7 and 6. No multivalent effect was observed for hCA IX and hCA
XII. The difference of the effect was hypothesized to come from steric hindrance effects as hCA I and II
are monomeric and hCA IX and XII dimeric enzymes. This may also suggest that multivalent binding
occurs through enzyme clustering. [14]
Currently, other silica nanoobjects are investigated as potential multivalent systems with potential
applications in the field of carbonic anhydrase inhibition. [15]
2.3. Gold Nanorods
Nanorods did become particularly attractive within the nanomaterial-based compounds for
biomedical applications, as they possess specific optical and thermal features that make them proper
innovative tools. Nanorods are perfectly suited for Near-InfraRed light (NIR) absorption and conversion
of its energy into thermal radiation with the generation of very minimal structural defects to the
material after its exposure to multiple cycles [16–18]. Such an effect referred as Surface Plasmonic
Resonance (SPR), is well known in nanodevices [16–18]. Nanorods have the advantage to possess
their SPR-inducing frequency within the NIR spectral window (i.e., 750–1200 nm), and that allows
them to make use of the deep penetration ability and low interference with biological tissues of this
radiation [16,19]. In this contest, we proofed that CAI coated nanorods selectively target hypoxic
tumor cells and determine death after exposure to NIR [16].
The synthesis of gold nanorods 15 was achieved by means of autocatalytic reduction of chloroauric
acid with ascorbic acid in the presence of cetrimonium bromide, silver nitrate, and ultra-small gold
nanospheres according to the procedure described in the literature [20]. Then the gold nanorods were
subjected to PEGylation with commercially available heterobifunctional PEG strands composed of 90%
α-mercapto-ω-methoxy and 10% α-mercapto-ω-carboxy PEG (MW ≈ 5000 g/mol). The PEGylated
nanorods obtained were further functionalized by means of standard N-hydroxysuccinimide/1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (NHS/EDCI) catalyzed amidation protocols to afford
the CAI ethylaminobenzenesulfonamide coated nanorods 16 and the 2-methoxyethylamine derivative
nanorods 17 as a negative control. The obtained gold shells 15, as well as the coated nanorod batches 16
and 17, were properly characterized for their physical and optical properties by mean of Transmission
Electron Micrograph (TEM) and optical extinction spectra (Figure 2).
As reported in Figure 2, the optical extinction characterization spectra of all nanorods were almost
superimposable as only small variations were detected. This implies that the particles did not aggregate
upon the modification and therefore were able to retain their optical features [21].
The most relevant aspect of the study for the purposes of this review is the assessment of the
biological features of the CAI coated nanorods, which showed no cytotoxicity on human colorectal
carcinoma HCT116 (HCT) and human mammary adenocarcinoma MDA-MB-231 (MDR) cells after
exposure to 24 h. Both HCT and MDR cell lines under normoxic and hypoxic conditions were
incubated with CAI- and 2-methoxyethylamine capped nanorods 16 and 17 and subjected to silver
staining. The corresponding optical micrographs clearly visualized the preferential accumulation
of gold nanorods for both HTC and MDR cell cultures incubated under hypoxia and treated with
CAI-functionalized nanorods 16 (Figure 3). Such results were also confirmed with quantitative analyses,
which accounted for the HTC cell lines retaining remarkable amounts of gold nanoparticles with
respect to the MDR series (data not reported here). Overall such results were in agreement with our
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hypothesis on the strong interactions occurring between the sulfonamides end-capping of the nanorods
with the membrane expressed and hypoxia-induced hCA IX [21].
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Figure 3. 350 µm × 250 µm Optical micrographs of HCT or MDA cells in normoxia (N) and hypoxia (H),
treated without particles (Control) or with 100µM of CAI-terminated particles 16 or 2-methoxyethylamine-
(Meth.) 17 and finally stained with silver [21].
The SPR-induced effects of the synthesized coated nanorods on HTC cell cultures was assessed
both under normoxic and hypoxic conditions. The SPR was induced by using a NIR radiation at 810
nm with a 5 min exposure time and power densities comprised between 50 and 150 W/cm2 (Figure 4).
As reported in Figure 4, the HTC hypoxic cells incubated with CAI-conjugated nanorods 16 were
killed using a laser with a power density of 50 W/cm2. The scale-up of the radiation densities determined
more extensive cellular damages. Hypoxic cells treated with 2-methoxyethylamine-modified particles
17 remained viable up to 150 W/cm2. Cell death was also observed when normoxic conditions were
considered. In this case, the cultures reported damages only when a radiation density threshold of
120 W/cm2 was reached. Such an effect was properly ascribed to the residual nonspecific uptake of
CAI-coated nanoparticles 16, as seen by spectrophotometry (results not reported). This study was the
first to report and successfully proof the biomedical application of CAI coated nanorods as potential
tools for the treatment of hypoxic tumors and therefore expressing the hypoxia-induced hCA IX
isoform. Further studies using the in vivo model of the disease will be necessary in order to give full
credit to the research outcomes.
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Figure 4. 470 µm × 400 µm Optical micrographs of HCT cells treated with 100 µM Au particles 16,
17 with different terminations and under hypoxia (H) or normoxia (N), and then excited with light at
810 nm and different power density for 5 min. After fixation, cells were stained with trypan blue [21].
3. Poly(Amidoamine) (PAMAM) Dendrimers
Dendrimers are defined as repetitively branched molecules that assume spherical and symmetrical
morphology. Dendrimeric scaffolds have been found useful for various applications such as the
biomedical ones, which are pertinent for the purposes of this review [22]. Some of us were the first
to report CAI functionalized poly(amidoamine) (PAMAM) dendrimers as potential drug delivery
systems for the management of ocular hypertension in glaucomatous patients [23,24]. The same
authors explored any multivalent effect on the CAs from pathogens (i.e., Vibrio cholerae, Trypanosoma
cruzi, Leishmania donovani chagasi, Porphyromonas gingivalis, Cryptococcus neoformans, Candida glabrata,
and Plasmodium falciparum) which was detected only for some of them [25]. The choice of PAMAM
scaffolds was mainly based on: (i) demonstrated bioadhesive features on the corneal surface [26];
(ii) the branched tree-like concentric layers, properly referred to as “generations-Gn”, allow a precise
number of functional groups to be incorporated in the macromolecule by means of standard protocols.
The synthetic chemistry approach applied is depicted in Scheme 4 and is based on amide
coupling reactions between the G0–G3 dendrimeric terminal primary amines with the freshly prepared
N-hydroxysuccinimide (NHS)-activated carboxylic ester of the phenyl sulfanilamide 18.
The activated ester 18, the sulfonamide functionalized dendrimers 19–22 and the reference CAI
dorzolamide (DRZ) were assayed in vitro for their inhibition properties against the physiologically
relevant hCA isoforms (i.e., I, II, IX, and XII) and the data are reported in Table 2 [23].
Overall, the obtained kinetic data showed the dendrimeric derivatives 19–22 possess inhibition
potencies towards the hCAs tested, which progressively increase with the generations (Table 2).
Such a trend was particularly evident for the hCA isoforms II and XII as the G2, and G3 dendrimeric
generations reached sub-nanomolar inhibition values (Table 2). As reported in Table 2, effects of
multivalence were clearly observed for the four generations of CAI coated dendrimers explored in
comparison with the monovalent CAI 1 (Table 1). Such an effect was particularly evident in the case of
hCA II and XII, where the decrease of the inhibition constants (KIs) from G0 to G3 registered potency
improvements (rp) of 9142 for hCA II and of 6333 for hCA XII respectively. The rp normalized data
onto the sulfonamide units (n) inserted in each dendrimer (rp/n) were of 285.7 for hCA II and of 197.9
for hCA XII, respectively, thus indicating significant multivalency effects.
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Table 2. CA inhibition data against isoforms hCA I, II, IX, and XII with compounds 19–22 and AAZ
and DRZ as standards, by a stopped-flow CO2 hydrase assay.
Compound
KI (nM) *
hCA I hCA II hCA IX hCA XII
18 7800 640 475 380
19 (G0) 24.1 10.4 34.7 9.3
rp 323 61 13 40
rp/n 80.9 15.3 3.4 10.2
20 (G1) 12.0 3.1 20.5 1.1
rp 650 206 23 345
rp/n 81.2 25.8 2.8 43.1
21 (G2) 10.8 0.93 8.6 0.94
rp 722 688 55 404
rp/n 45.13 43 3.5 25.3
22 (G3) 10.5 0.07 5.1 0.06
rp 742 9142 93 6333
rp/n 23.21 285.7 2.9 197.9
AAZ 250 12 25 5.7
DRZ 50000 9 52 3.5
* Errors in the range of ± 5% of the reported values, from three different assays. rp: relative potency = KI(18)/KI(Gn).
rp/n: relative potency/number of sulfonamide units.
The same study reported the successful application of such compounds for the management
of ocular hypertension in an animal model of glaucoma. Quite interestingly, all G0–G3 CAI coated
dendrimers showed intraocular pressure (IOP) lowering effects far more superior and time lasting when
compared to the standard CAI DRZ all used at the same concentration (i.e., 2%). In particular, the CAI
derivatized G1–G3 generations showed a remarkable ability to maintain constantly reduced IOP values
over the experiment time course of 120 h. Although additional studies were not conducted, it is
reasonable to speculate that such performances were obtained by means of various effects collectively
taking place, which among others, include the release of the CAI units by hydrolytic processed [26]
and trans-corneal penetration of the CAI-dendrimers.
4. Other Platforms (Polyols, Fullerene, Cyclopeptide)
Research works have also been described with other multivalent platforms bearing different types
of CA inhibitor chemotypes. Xanthate and coumarin chemotypes were, respectively, described as
multimeric CAIs by Vincent group using respectively fullerene platforms 23 and polyol-scaffolds 24–26
(Figure 5) [27,28]. These multivalent systems were elaborated using the click-type copper-mediated
azide-alkyne cycloaddition (CuAAC) reaction, as shown in Figure 5. The multivalent systems were
in each case, better inhibitor than the monovalent inhibitor, but the weak multivalent effect was
observed. However, both studies showed that the multimeric presentation of the CAIs can influence the
selectivity against the different isoforms (cytosolic vs. membrane bounds). In the case of polyol-scaffold
bearing xanthate chemotypes, weak inhibitory activity (micromolar range) and weak multivalent
effects were observed. Nevertheless, improved potency and selectivity were noticed compared with
the monovalent analogs [27,28]. The most important results in this work were the demonstration that
inactive monovalent inhibitors on hCA II and hCA IX (inhibition constant >100 µmol) can become
active when they are ligated on a multimeric platform, with inhibitory activity ranging from 10 to
70 µmol.
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In 2017, our group reported new multimeric CAIs using functionalized peptide scaffolds as
a multivalent platform [29]. We constructed cyclic and linear peptides bearing multiple reactive
glyoxylic aldehyde functions able to be conjugated chemoselectively with sulfonamide inhibitors
under mild conditions and in high yields using metal-free click-type bioconjugation methodologies
such as hydrazone and oxime ligations (Figure 6).
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Figure 6. Multivalent CA inhibitors from functionalized peptide scaffolds with oxime or hydrazide
ligation (in red). [30].
Both peptide scaffolds 25 and 26 were synthesized using automated solid-phase peptide synthesis
(SPPS). To prepare the cyclic peptide, cyclization under high-dilution conditions was followed by
oxidative cleavage of serine side-chains in order to unmask the glyoxylic aldehyde groups. The synthesis
of the linear peptide was realized via acetylation of the N-terminal position, followed by cleavage
and deprotection, and finally, oxidative cleavage of serine side-chains. Hydrazone and oxime ligation
were performed respectively with the corresponding monovalent hydrazide or oxyamine sulfonamide
inhibitors. [29]
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The inhibitory activity showed that multivalent oxime conjugates 27 and 28 were less potent
than the monovalent system against the membrane-bound isoforms hCA IX and hCA XII. The only
improvement of potency was observed against hCA II with a relative potency (rp) increased by 13- and
5-fold, respectively.
Multivalent hydrazide conjugates 29 and 30 showed an improved potency against hCA II, hCA
IV, and hCA XII compared to the monovalent inhibitors. Moderate multivalent effects against isoforms
II, IV, and XII with rp/n > 1 were characterized. In each case, the pre-organized multivalent conjugates
made of the cyclic scaffold, 27 and 29, were more potent than the conjugate made of the linear scaffold.
The results obtained in this study suggest that the multivalent effects act through an increase in the
local concentration of CA inhibitors against the enzymes. [30]
5. Conclusions and Prospects
The multivalency approach was successfully applied to the design of CA inhibitors belonging to a
variety of classes (sulfonamides, dithiocarbamates, carboxylates, etc.) [29,31,32] and applying various
multimeric systems, such as gold nanoparticles, gold nanorods, silica nanoparticles, dendrimers,
fullerenes, polyols, peptides, etc. In most cases, interesting multimeric effects were observed for these
inhibitors compared to the corresponding “monomeric” CA inhibitor from which they were derived.
However, in many other cases, the differences were relatively small. This may probably be due to some
of the constraints that were imposed on the scaffolds of the CAIs used in the syntheses, and/or to the
various platforms employed for derivatization. Thus, although the chemistry of the CAI allows for a
huge variety of CAIs and CA inhibition mechanisms, the platforms used to date are rather limited,
with few NPs, just one example of dendrimer and quite a few other investigated such scaffolds. Thus,
more intense research on the derivatization of novel platforms, with improved (or diverse) properties
is to be expected in the future. Furthermore, with few exceptions, the sulfonamides were the most
investigated chemotype as CAI warhead. However, many other much more interesting chemotypes
are available nowadays [29,31,32], which might lead to multivalent CAIs with improved desired
properties. We expect in the future years a large increment in this part of our knowledge of CAIs.
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